Education
About Us
Working with TipRanks
Follow Us
Spyre Therapeutics (SYRE)
NASDAQ:SYRE
SYRE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$10.91 - $40.26
Previous CloseN/A
Volume84.75K
Average Volume (3M)511.30K
Market Cap
$1.02B
Enterprise Value$382.05M
Total Cash (Recent Filing)$526.58M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)2.3
Beta1.80
Next Earnings
Nov 06, 2025EPS Estimate
-0.78Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.49
Shares Outstanding60,400,960
10 Day Avg. Volume462,051
30 Day Avg. Volume511,303
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.38
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.72
Forecast
1Y Price Target
$55.20Price Target Upside227.40% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Bulls Say, Bears Say
Bulls Say
Clinical TrialsSpyre Therapeutics reported positive Phase 1 results with their two long-acting anti-TL1A monoclonal antibodies, SPY002 and SPY072, which showed best-in-class properties.
Financial PositionSpyre Therapeutics has a strong financial position with $526.6 million in cash, cash equivalents, and marketable securities, expected to support operations into 2028.
Research PipelineThe initiation of the Phase 2 SKYLINE-UC platform study to evaluate Spyre's assets in ulcerative colitis demonstrates progress in their research pipeline.
Bears Say
Clinical Trials RiskEnrollment in Ph2b UC trial of LLY's oral α4β7i appears slower than anticipated, which represents a risk to all early stage UC trials.
Competitive PressureAny disappointing data from JNJ's DUET trials could pressure SYRE stock.
Market UncertaintyThere is uncertainty regarding when JNJ will report results that could significantly impact Spyre's stock.
Spyre Therapeutics News
SYRE FAQ
What was Spyre Therapeutics’s price range in the past 12 months?
Spyre Therapeutics lowest stock price was $10.91 and its highest was $40.26 in the past 12 months.
What is Spyre Therapeutics’s market cap?
Spyre Therapeutics’s market cap is $1.02B.
When is Spyre Therapeutics’s upcoming earnings report date?
Spyre Therapeutics’s upcoming earnings report date is Nov 06, 2025 which is in 82 days.
How were Spyre Therapeutics’s earnings last quarter?
Spyre Therapeutics released its earnings results on Aug 05, 2025. The company reported -$0.49 earnings per share for the quarter, beating the consensus estimate of -$0.754 by $0.264.
Is Spyre Therapeutics overvalued?
According to Wall Street analysts Spyre Therapeutics’s price is currently Undervalued.
Does Spyre Therapeutics pay dividends?
Spyre Therapeutics does not currently pay dividends.
What is Spyre Therapeutics’s EPS estimate?
Spyre Therapeutics’s EPS estimate is -0.78.
How many shares outstanding does Spyre Therapeutics have?
Spyre Therapeutics has 60,400,960 shares outstanding.
What happened to Spyre Therapeutics’s price movement after its last earnings report?
Spyre Therapeutics reported an EPS of -$0.49 in its last earnings report, beating expectations of -$0.754. Following the earnings report the stock price went down -5.394%.
Which hedge fund is a major shareholder of Spyre Therapeutics?
Currently, no hedge funds are holding shares in SYRE
Spyre Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$55.20 (227.40% Upside)
$55.20 (227.40% Upside)
Blogger Sentiment
Bullish
SYRE Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 3.5%
Last 30 Days ▲ 3.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-31.82%
12-Months-Change
Fundamentals
Return on Equity
-41.00%
Trailing 12-Months
Asset Growth
23.57%
Trailing 12-Months
Company Description
Spyre Therapeutics
Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.
SYRE Stock 12 Month Forecast
Average Price Target
$55.20
▲(227.40% Upside)
Technical Analysis
Ownership Overview
9.65% Insiders
24.75% Mutual Funds
0.06% Other Institutional Investors
54.87% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---